The following are some key points that we have chosen to highlight in connection with the report:

• Decreasing sales but increasing number of laboratories with the GA-map® system installed
• Improved EBITDA-result through strong gross margin and cost control
• Rights issue to finance commercial investments
• Launch of a new consumer test in China

To summarize, Genetic Analysis results during Q1-25 were somewhat weaker than expected, but where sales are expected to fluctuate between quarters as earlier mentioned. Analyst Group argues that nothing has changed in the long-term growth outlook, as the GA-map® system has been installed in an increasing number of laboratories and the beneficial market development is unchanged. Despite the decrease in sales, the strong gross margin and cost control resulted in an improved EBITDA-result.

Read Analyst Group’s comment on the report here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
 
This is a press release from Analyst Group regarding the publication of a comment on Genetic Analysis. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.